Review of 20 cases of advanced mucosal melanoma

Key Points

• To evaluate overall survival and response rates in advanced mucosal melanoma treated with immunotherapies and targeted therapies.
• Reviewed 20 cases of advanced mucosal melanoma treated since 2014.
• Assessed the effectiveness of immune checkpoint inhibitors and BRAF/MEK inhibitors as first-line therapies.
• Compared the outcomes of monotherapy with anti-PD-1 antibodies to combination therapy with anti-PD-1 and anti-CTLA-4 antibodies.
• 5-year survival rates for mucosal melanoma were lower compared to other melanoma types.
• Combination therapy tended to show better effectiveness than monotherapy with anti-PD-1 antibodies.
• Mucosal melanoma cases often lack BRAF mutations, leading to a preference for immune checkpoint inhibitor therapy.